GLGill Little

Gill Little

*This is an algorithmically generated author record based on publicly available information.

Gill Little has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • James Reif

    Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA

    1 shared publication
  • Jason Rossi

    Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA

    1 shared publication
  • Linli He

    Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA

    1 shared publication
  • Melanie Marguerit

    Selcia Ltd., Fyfield Business & Research Park, Fyfield Road, Ongar, Essex, CM 0GS, UK, http://www.selcia.com

    1 shared publication
  • Renee Roemmele

    Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA

    1 shared publication
  • Roger Bakale

    Teva Pharmaceuticals, Chemical Synthesis Center, 383 Phoenixville Pike, Malvern, PA 19355-9603, USA

    1 shared publication

Latest Publications

  • Total Synthesis of [14C]‐Labelled Homoharringtonine

    by Melanie Marguerit, Gill Little, Yi Wang, Linli He, Shawn Allwein, James Reif, Jason Rossi, Renee Roemmele, Roger Bakale

    A total synthesis of enantiomerically pure [14C]‐labelled (–)‐homoharringtonine in 17 steps is reported. This synthetic process enabled the production of Good Manufacturing Practice (GMP) compliant (–)‐[14C]homoharringtonine that was used in a human mass balance study that was a post‐approval commitment to the U.S. Food and Drug Administration. (–)‐Homoharringtonine, also called omacetaxine mepesuccinate, is approved to treat adult patients with chronic myeloid leukemia (CML), a blood and bone marrow disease. In November 2012, the product was commercialised as Synribo® in the U.S., marketed by Teva Pharmaceuticals.